WO2024171082 - STABLE PROTEIN COMPOSITIONS OF ANTI-PD1 ANTIBODY
National phase entry:
Publication Number
WO/2024/171082
Publication Date
22.08.2024
International Application No.
PCT/IB2024/051388
International Filing Date
14.02.2024
Title **
[English]
STABLE PROTEIN COMPOSITIONS OF ANTI-PD1 ANTIBODY
[French]
COMPOSITIONS DE PROTÉINES STABLES D'ANTICORPS ANTI-PD1
Applicants **
SUN PHARMACEUTICAL INDUSTRIES LIMITED
Inventors
SHAH, Bhavik Kumar
SHARMA, Manish
JOGANI, Viralkumar Vinodlal
KHOPADE, Ajay Jaysingh
NAGARAJA, Ravishankara Madavati
CHOUHAN, Pankaj Singh
Priority Data
202321010367
16.02.2023
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2651 | |
| EPO | Filing, Examination, Granting | 18290 | |
| Japan | Filing, Examination, Granting | 2776 | |
| South Korea | Filing, Examination, Granting | 3159 | |
| USA | Filing, Examination, Granting | 15940 |
Total:
42,816
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The invention relates to stable compositions of an antibody against human programmed death receptor PD-1, or antigen binding fragments thereof. The invention further provides methods for treating various cancers with stable formulations of the invention. The present invention relates to pharmaceutical compositions of an anti-PD1 antibody comprising a buffer, a sugar or sugar alcohol and a surfactant. In some embodiments of the invention, the formulations may be administered to a subject by intravenous or subcutaneous administration.[French]
L'invention concerne des compositions stables d'un anticorps dirigé contre le récepteur de mort programmée humaine PD-1, ou des fragments de liaison à l'antigène de celui-ci. L'invention concerne en outre des procédés de traitement de divers cancers avec des formulations stables de l'invention. La présente invention concerne des compositions pharmaceutiques d'un anticorps anti-PD1 comprenant un tampon, un sucre ou un alcool de sucre et un tensioactif. Dans certains modes de réalisation de l'invention, les formulations peuvent être administrées à un sujet par administration intraveineuse ou sous-cutanée.